We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Hip Resurfacing System Eases Arthritis Pain

By HospiMedica staff writers
Posted on 04 Sep 2007
A new hip arthroplasty resurfacing system is intended for reduction or relief of pain and/or improved hip function in patients with non-inflammatory degenerative arthritis or inflammatory arthritis.

The Cormet Hip Resurfacing system is a metal-on-metal resurfacing artificial hip replacement system, surgically implanted to replace a hip joint. More...
The system relieves hip pain and improves hip function by replacing parts of the hip joint that have been severely damaged by degenerative joint diseases such as osteoarthritis, rheumatoid arthritis, traumatic arthritis, dysplasia, or avascular necrosis. The system is intended for patients who, due to their relatively younger age or increased activity level, may not be suitable for traditional total hip replacement due to an increased possibility of future hip joint revision.

The system has two parts: an acetabular component--a socket in the shape of a shallow cup--and a femoral resurfacing component in the form of a ball head. During the procedure, the acetabular component replaces the damaged surface of the hip socket, while the femoral resurfacing component covers the femoral head. The components, made from highly polished metal, articulate within each other, forming a coupled bearing. The Cormet Hip Resurfacing system is manufactured by Corin (Cirencester, UK). The U.S. Food and Drug Administration (FDA) orthopedic and rehabilitation devices panel voted in favor of Corin's premarket approval application (PMA).

"We pioneered metal-on-metal resurfacing technology in the late 1980s, and our Cormet device has been sold and successfully implanted around the world for almost a decade,” said Ian Paling, Corin's CEO. "We are very confident that the opportunities for Cormet in the U.S. are substantial, as all our market research points to significant demand for this hip resurfacing technology, which is especially attractive to the younger, active ‘baby-boomer' generation.”


Related Links:
Corin

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Digital Color Doppler Ultrasound System
MS22Plus
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.